| abstract |
The invention relates to the use of a combination of active ingredients, consisting essentially of rhaponticin and deoxyrhaponticin, their functional derivatives or the stereoisomeric forms thereof, in the form of salts or phenol respectively, for producing an agent for the prevention and/or treatment of diseases, whose occurrence and/or progress is associated with an increased IL-6 serum level and/or whose occurrence and/or progress can be treated by a dose of a selective oestrogen receptor β (ER-β) agonist. |